Brean Lifts PT on Inovio Pharma (INO) to $5; Expects Strong Data from VGX-3100 Phase 2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Strong earthquake rocks north-central Venezuela, capital Caracas
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Inovio Pharmaceuticals (INO) Price Target Lifted to $6 at Maxim Group
March 18, 2014 7:12 AM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals (NYSE: INO) and doubled his price target from $3 to $6 following fourth quarter results, saying the best is still ahead.
Kolbert notes the company has plenty of capital runway for... More
Inovio Pharma (INO) Posts Q4 Loss of 4c/Share; Offers Corp. Update
March 17, 2014 6:06 AM EDTInovio Pharmaceuticals, Inc. (AMEX: INO) reported Q4 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.36 million.
orporate Update
Corporate Development
In a major corporate development for the Company, Roche and Inovio entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA vaccine products targeting prostate cancer and hepatitis B. Roche licensed Inovio's therapeutic vaccines INO-5150 for prostate cancer and INO-1800 for hepatitis B as well as the use of Inovio's CELLECTRA®... More
